NCT05228574

Treatment of Vascular Stiffness in ADPKD

Treatment of Vascular Stiffness in Patients With Autosomal Dominant Polycystic Kidney Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Erasmus Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease characterized by cystic kidneys and caused by mutations in the polycystic kidney disease and other rare genes. It is associated with salt-sensitive hypertension, which accounts for the majority of morbidity and mortality. About 70% of patients with ADPKD develop hypertension, prior to the onset of kidney function decline. Early onset hypertension, despite its treatment, is independently associated with rapid kidney function decline. The investigators hypothesize that a high-sodium diet in patients with ADPKD is required for the development of vascular stiffness, which precedes hypertension, and that treatment with amiloride reverses this phenomenon.

Detailed description

Objective of the study: The investigators aim to investigate if arterial stiffness is exacerbated due to a high-salt diet in patients with ADPKD. The investigators also aim to explore whether treatment with amiloride prevents the arterial stiffness caused by a high-salt diet. Study design: Randomized, double blinded and placebo-controlled clinical trial with open-label treatment with amiloride Study population: Adults with ADPKD with an estimated glomerular filtration rate (CKD-EPI) of ≥ 60 ml/min/1.73m2 Intervention: All participants will be subjected to a low-salt diet (3,5 grams/day) throughout the study for a total of 6 weeks. After a run-in period of 2 weeks, participants will be randomized into two treatment groups: Group 1: Sodium chloride capsules (6 grams/day) for 2 weeks, combined with amiloride (20 mg/day) in last 2 weeks Group 2: Placebo capsules for 2 weeks, combined with amiloride (20 mg/day) in last 2 weeks. Primary study parameters/outcome of the study: The three primary outcomes of this study are a difference in central arterial stiffness (pulse wave velocity, PWV) between: 1. The high-salt group versus low-salt group; 2. The high-salt group: before versus after amiloride treatment; 3. The low-salt group: before versus after amiloride treatment. The burden of participation includes: * A dietary salt restriction of 3.5 grams/day for a total period of 6 weeks * Salt supplementation or placebo for a total period of 4 weeks * Drug intervention with amiloride during the last 2 weeks * Hospital visits

Conditions

• Autosomal Dominant Polycystic Kidney

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Sodium chloride (NaCl)	Sodium chloride capsules 6 grams per day for 4 weeks.
DIETARY_SUPPLEMENT	Placebo	Placebo capsules, 6 grams per day for 4 weeks.
DRUG	Amiloride Hcl 5mg Tab	Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.

Timeline

• Start date: 2022-03-11
• Primary completion: 2025-06-18
• Completion: 2025-06-18
• First posted: 2022-02-08
• Last updated: 2025-08-17

Locations

1 site across 1 country: Netherlands